Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone650-641-2100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$108.47 million
Profitability
Miscellaneous
Employees393
Next Earnings Date8/7/2019 (Estimated)
OptionableOptionable
Intersect ENT (NASDAQ:XENT) Frequently Asked Questions
What is Intersect ENT's stock symbol?
Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."
How were Intersect ENT's earnings last quarter?
Intersect ENT Inc (NASDAQ:XENT) posted its earnings results on Monday, May, 6th. The medical equipment provider reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.05. The medical equipment provider earned $26.70 million during the quarter, compared to analyst estimates of $26.34 million. Intersect ENT had a negative net margin of 24.99% and a negative return on equity of 22.90%. The firm's revenue was up 8.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.21) earnings per share. View Intersect ENT's Earnings History.
When is Intersect ENT's next earnings date?
What guidance has Intersect ENT issued on next quarter's earnings?
Intersect ENT updated its first quarter 2019 earnings guidance on Monday, February, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $26-26.5 million, compared to the consensus revenue estimate of $27.5 million.Intersect ENT also updated its FY 2019 guidance to EPS.
What price target have analysts set for XENT?
6 analysts have issued twelve-month price targets for Intersect ENT's stock. Their predictions range from $20.00 to $40.00. On average, they expect Intersect ENT's stock price to reach $30.95 in the next year. This suggests a possible upside of 20.5% from the stock's current price. View Analyst Price Targets for Intersect ENT.
What is the consensus analysts' recommendation for Intersect ENT?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Intersect ENT.
What are Wall Street analysts saying about Intersect ENT stock?
Here are some recent quotes from research analysts about Intersect ENT stock:
- 1. Northland Securities analysts commented, "We were not allowed to ask questions on the call, but to any rational observer, it is hard to reconcile commentary about the rosy outlook and the CEO’s departure. The abrupt CEO change at a pivotal time in the company’s history telegraphs implicit weakness in the outlook. Downgrading to UP / $20 PT. Key Points All eyes are on level of J-code reimbursement for SINUVA beginning Jan 2020. Company mentioned billing to the tune of 135x that of a 10mcg MF injectable drug. Recent decisions by Anthem and Aetna (drug formulation & medical policy, respectively) continues. The use of an unassigned J-code continues, and roughly 185 physicians engaged in buy & bill" by end of in Q4-18. Average buy in these accounts = 1 unit. ASP = $1,000 / implant. Pre-auth times for SINUVA have come down from ~1month around Q3-18 to a current run rate of 2-weeks or so." (5/7/2019)
- 2. According to Zacks Investment Research, "Over the past year, shares of Intersect ENT have underperformed the industry it belongs to. Escalating costs and expenses continue to weigh on the company’s margins. This apart, the pricing scenario is persistently tough for Intersect ENT. Strong competitors in the large medical device market also pose a tough challenge. On a positive note, within a short span of time, the SINUVA line of business has made a considerable progress with market access and field force balance. Within the company’s Propel line, Intersect ENT registered 10% growth in the top line during the fourth quarter 2018, driven by an expanded usage of Contour among both the current as well as the new physicians." (5/3/2019)
- 3. BTIG Research analysts commented, "Intersect reported Q4 revenue in line with its preannouncement. Guidance of $123M-$127M (also given previously) remains just below the Street’s $127.2M but not surprising given some conservatism early in the year. The company will no longer guide SINUVA but is aware of Street estimates and will see how sales play out. The big surprise was operating expense guidance of $135-137M which was well above most estimates. We think shares will be pressured Tuesday. While a good portion of this increased spend will be R&D for a new drug-coated balloon, it is also clear that much of XENT’s growth is coming through head count. While Intersect will have significantly more data coming, we continue to remain cautious around reimbursement for SINUVA. We do not know what will happen with the re- proposed J-Code and we are not sure how many insurance companies will decide to pay more than once per year." (2/26/2019)
- 4. Canaccord Genuity analysts commented, "We remain buyers ahead of trial data coming up in 4Q18 We believe the stock’s pullback presents opportunity ahead of a catalyst-rich period that is coming up in the near to medium-term. Specifically, we await results on long- term safety of rimegepant (acute treatment of migraine) and a Phase 3 trial on the orally-dissolving tablet (ODT) formulation of rimegepant. Given the behavior of the molecule in two Phase 3 trials so far (see here) and a validated mechanism (Allergan also reported positive results for its ubrogepant; see here), we expect these results to support a potential filing of rimegepant in 2019. a more detailed list of BHVN-related catalysts. We also continue to believe that rimegepant could be a meaningful player in the market for the acute treatment of migraine, and we are reiterating our BUY on BHVN." (8/1/2018)
Has Intersect ENT been receiving favorable news coverage?
News stories about XENT stock have been trending somewhat positive recently, InfoTrie reports. The research firm ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Intersect ENT earned a media sentiment score of 1.5 on InfoTrie's scale. They also gave news stories about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days.
Who are some of Intersect ENT's key competitors?
Some companies that are related to Intersect ENT include NuVasive (NUVA), Merit Medical Systems (MMSI), Cantel Medical (CMD), Glaukos (GKOS), Nevro (NVRO), Irhythm Technologies (IRTC), Atrion (ATRI), Shockwave Medical (SWAV), Mazor Robotics (MZOR), Silk Road Medical (SILK), Cardiovascular Systems (CSII), K2M Group (KTWO), AtriCure (ATRC), Cryolife (CRY) and Orthofix Medical (OFIX).
What other stocks do shareholders of Intersect ENT own?
Who are Intersect ENT's key executives?
Intersect ENT's management team includes the folowing people:
- Ms. Lisa D. Earnhardt, CEO, Pres & Director (Age 49)
- Ms. Jeryl L. Hilleman, Chief Financial Officer (Age 61)
- Mr. David A. Lehman, Gen. Counsel & Sec. (Age 58)
- Mr. Drake R. Parker, Advisor of Strategic Initiatives (Age 55)
- Ms. Christine R. Kowalski, Chief Operations Officer (Age 62)
Who are Intersect ENT's major shareholders?
Intersect ENT's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.64%), Wellington Management Group LLP (5.18%), Federated Investors Inc. PA (2.59%), Westfield Capital Management Co. LP (2.09%), FMR LLC (2.02%) and Morgan Stanley (1.99%). Company insiders that own Intersect ENT stock include Dana G Jr Mead, David Aaron Lehman, Frederic H Moll, Gwen R Carscadden, Jeryl L Hilleman, Lisa D Earnhardt, Richard E Kaufman, Robert H Binney, Jr and Susan P Stimson. View Institutional Ownership Trends for Intersect ENT.
Which institutional investors are selling Intersect ENT stock?
XENT stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., Federated Investors Inc. PA, SG Americas Securities LLC, Citigroup Inc., Goldman Sachs Group Inc., Westfield Capital Management Co. LP and Lombard Odier Asset Management USA Corp. Company insiders that have sold Intersect ENT company stock in the last year include David Aaron Lehman, Jeryl L Hilleman, Lisa D Earnhardt, Richard E Kaufman, Robert H Binney, Jr and Susan P Stimson. View Insider Buying and Selling for Intersect ENT.
Which institutional investors are buying Intersect ENT stock?
XENT stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Morgan Stanley, William Blair Investment Management LLC, Osterweis Capital Management Inc., Great Lakes Advisors LLC, Jennison Associates LLC, Artisan Partners Limited Partnership and Perceptive Advisors LLC. View Insider Buying and Selling for Intersect ENT.
How do I buy shares of Intersect ENT?
Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Intersect ENT's stock price today?
One share of XENT stock can currently be purchased for approximately $25.69.
How big of a company is Intersect ENT?
Intersect ENT has a market capitalization of $802.71 million and generates $108.47 million in revenue each year. The medical equipment provider earns $-22,920,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. Intersect ENT employs 393 workers across the globe.
What is Intersect ENT's official website?
How can I contact Intersect ENT?
Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]
MarketBeat Community Rating for Intersect ENT (NASDAQ XENT)
MarketBeat's community ratings are surveys of what our community members think about Intersect ENT and other stocks. Vote "Outperform" if you believe XENT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XENT will underperform the S&P 500 over the long term. You may vote once every thirty days.
